Heron Therapeutics Inc

HRTXNASDAQ · USD
0.26USD0.00 (-3.26%)
442

Heron Therapeutics Inc (HRTX) Expected Move

HRTX expected move through Nov 20, 2026 is 384.6%, with 0 days to expiration. The implied range is -$0.74 to $1.26, based on the previous trading day's options prices.

Read more

Tracking the HRTX expected move helps you see how far Heron Therapeutics Inc's options market is pricing the stock to travel over a given period — whether that's the next day, week, or earnings cycle. Heron Therapeutics Inc's expected move is derived directly from option premiums and gives you an objective range to plan trades, set strikes, and manage risk. Use our scanner to monitor the HRTX expected move for this week's options, in real time.

The expected move is typically calculated from at-the-money straddle prices (or a blend of straddles and strangles) and represents roughly a one-standard-deviation range over the chosen timeframe. For HRTX, comparing the implied expected move to actual realized moves over similar windows tells you whether the options market has historically overestimated or underestimated volatility. The HRTX expected move for this week's options pricing is especially useful for short-dated traders, earnings players, and anyone selling premium who needs to know where the market thinks Heron Therapeutics Inc is unlikely to go.

Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy.

Iron condors, weekly premium sales, directional swing trades — they all live or die by where the market thinks the stock won't go. Our scanner tracks the HRTX expected move across every expiration, benchmarks it against realized moves, and shows you when implied ranges are out of line with history. The Heron Therapeutics Inc expected move for this week's options is the fastest read on short-term risk, which gives you a quick way to interpret what the options market thinks about HRTX.

HRTX Price

EARN
EM

Drag chart to pan. Drag axes to zoom.

ExpirationDTEExpected move (USD)Expected move (%)Upper priceLower price
Nov 20, 20260$1.00384.6%$1.26-$0.74
Dec 18, 202628$30.4311,701.9%$30.69-$30.17
Jan 15, 202756$3.481,336.5%$3.74-$3.22
Mar 19, 2027119$10.904,192.3%$11.16-$10.64

As of Nov 19, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →